Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 3, 2008

Cell Genesys and Takeda End Partnership for Prostate Cancer Immunotherapy

  • Takeda Pharmaceutical has ended its collaboration with Cell Genesys related to GVAX immunotherapy for prostate cancer. After two separate Phase III trials were stopped short, the firms along with wholly owned subsidiary Millennium: The Takeda Oncology Company decided to suspend development of the drug.

    Under the development and commercialization deal between the companies, Takeda will return all commercial rights to GVAX immunotherapy for prostate cancer to Cell Genesys and make certain wind-down payments in connection with the phasing out of the remaining clinical development activities.

    Cell Genesys is also evaluating GVAX cancer immunotherapy in leukemia, pancreatic cancer, and lung cancer.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »